Status:
COMPLETED
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Lead Sponsor:
Bayer
Collaborating Sponsors:
Novartis
Conditions:
Bronchiectasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.
Detailed Description
Safety issues are addressed in the AE section. There is no standardised and unanimously accepted definition of exacerbation in COPD; 4 definitions are widely used: (1) using a combination of 3 cardina...
Eligibility Criteria
Inclusion
- Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or post pneumonic bronchiectasis
- Stable pulmonary status and stable regimen of standard treatment at least for the past 30 days
Exclusion
- Forced Expiratory Volume 1 \< 35% or \> 80%
- Allergic bronchopulmonary aspergillosis
- Immunodeficiency disease requiring immunoglobulin replacement
- Inflammatory bowel disease
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT00930982
Start Date
June 1 2009
End Date
September 1 2010
Last Update
December 12 2014
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72205
2
La Jolla, California, United States, 92037
3
Denver, Colorado, United States, 80206
4
Farmington, Connecticut, United States, 06030